CJC-1295 and Ipamorelin
CJC-1295 and Ipamorelin are the most frequently paired compounds in growth hormone research, and the reason is mechanical rather than promotional: they act on two separate control points of the same axis. One changes how much growth hormone is released; the other changes how often. Studied alone, each moves a single variable. Studied together, they are used to model a combined amplitude and frequency response.
The short answer
CJC-1295 is a GHRH analog — it mimics the hypothalamic signal that instructs the pituitary to release growth hormone, which raises pulse amplitude. Ipamorelin is a GHRP — it works through the ghrelin receptor and simultaneously reduces somatostatin, the brake on release, which raises pulse frequency. Because the receptor targets do not overlap, the combined response reported in the literature is larger than either compound produces alone.
Side-by-side comparison
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Compound class | GHRH analog — a modified fragment of growth hormone releasing hormone (1–29). | GHRP — a selective growth hormone secretagogue acting at the ghrelin receptor (GHS-R1a). |
| Mechanism studied | Binds GHRH receptors on somatotroph cells, raising the amount of growth hormone released per pulse. | Activates GHS-R1a and suppresses somatostatin tone, increasing how often a pulse is triggered. |
| Effect on the GH pulse | Amplitude — a bigger pulse. | Frequency — more pulses, with the natural pulsatile pattern preserved. |
| Selectivity | Acts on the GHRH pathway only. | The most selective GHRP in the literature — minimal cortisol and prolactin cross-reactivity compared with GHRP-6 or hexarelin. |
| Half-life | Modified GRF (1–29) without DAC clears in roughly 30 minutes; the DAC version binds albumin and persists for several days. | Approximately two hours, matching a short physiological pulse window. |
| Handling | Lyophilized at -20°C; reconstituted with bacteriostatic water and stored at 2–8°C. | Identical storage profile — lyophilized frozen, reconstituted refrigerated. |
CJC-1295 in more detail
CJC-1295 is a synthetic analog of the first 29 amino acids of growth hormone releasing hormone, the active fragment of the native molecule. Four amino acid substitutions protect it from enzymatic degradation, so it survives long enough to reach GHRH receptors on pituitary somatotroph cells. Once bound, it triggers the same intracellular cascade the endogenous hormone does — the pituitary releases the growth hormone it has already synthesized and stored, rather than receiving hormone from an external source. That distinction is central to the research interest: the pituitary remains the rate-limiting participant, and negative feedback from IGF-1 and somatostatin still applies.
DAC versus no-DAC
The two forms behave very differently and are not interchangeable in a study design. Modified GRF (1–29), the no-DAC form, clears within about half an hour, which confines its effect to a single discrete pulse window — this is why it is the form usually paired with a GHRP. CJC-1295 with DAC carries a Drug Affinity Complex that binds serum albumin, extending the half-life to several days and producing a sustained elevation in circulating growth hormone rather than a pulse. Models built around pulsatility use the no-DAC form; models examining sustained exposure use DAC.
Ipamorelin in more detail
Ipamorelin is a pentapeptide growth hormone secretagogue that binds GHS-R1a, the ghrelin receptor. Its defining characteristic in the published literature is selectivity. Earlier GHRPs such as GHRP-6 and hexarelin also stimulate growth hormone release, but do so alongside meaningful increases in cortisol, prolactin and appetite signaling, which introduces confounding variables. Ipamorelin produces a comparable growth hormone response with far less of that cross-talk, which is precisely why it became the standard GHRP for controlled work: fewer secondary hormonal effects means a cleaner attribution of any observed outcome.
Why the combination is studied
- Non-overlapping receptors. A GHRH analog and a GHRP occupy separate binding sites, so their signals sum rather than compete for the same target.
- Somatostatin suppression. The GHRP lowers the inhibitory tone that would otherwise blunt the GHRH signal, so the same GHRH stimulus produces a larger measured release.
- Preserved pulsatility. Growth hormone is naturally released in pulses. Because both compounds act upstream on the pituitary, the pulsatile pattern is retained — a key reason this pair is favored over models that supply hormone directly.
Study design considerations
Timing dominates results in this area. Because the growth hormone axis is suppressed by circulating IGF-1 and by nutrient intake, protocols in the literature typically isolate administration from feeding, and align with the endogenous nocturnal pulse. Half-life matching matters too: pairing a two-hour GHRP with a multi-day DAC compound produces overlapping but desynchronized exposure windows, which complicates interpretation. Where the endpoint is a discrete pulse response, no-DAC CJC-1295 and Ipamorelin are the conventional pairing.
Purity matters in combination work
When two compounds are administered together, any contaminant in either lot is attributed to the combination. Every Muscle Pump 26 lot ships with a third-party Certificate of Analysis documenting 99%+ purity, so an observed response is attributable to the compounds themselves.
For research purposes only. Not for human consumption. Nothing on this page is medical advice or a therapeutic claim.